Sotatercept for right heart function in pulmonary hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with pulmonary arterial hypertension (PAH) that is either idiopathic (no known cause) or heritable.
- You have a blood test result showing NT-proBNP over 300 ng/L, which indicates some heart strain.
- You are not currently hospitalized for PAH, and have not had a major bleeding event or blood clots.
- You do not have diabetes, significant heart disease, or other serious health conditions that would interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the drug sotatercept affects blood vessels in the lungs. It may help people with group 1 pulmonary hypertension (high blood pressure in the lungs).
This study tests a new drug called sotatercept to help people with pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become too narrow, making the heart work harder. The drug may help improve how well your lungs and heart work together.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This trial tests a new medicine called sotatercept to see if it improves heart and lung blood vessel health in people with PAH. Participants will have special PET scans to measure changes.
This study tests a new medicine called sotatercept in Japanese children who have pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become narrow and stiff, making it harder for the heart to pump blood through them. The medicine may help improve how well their hearts and lungs work together.
This study is for people who have already taken part in a clinical trial of sotatercept for pulmonary arterial hypertension and done well enough to continue. It tests the long-term safety and effectiveness of staying on sotatercept, an investigational treatment that helps lower blood pressure in the lungs.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.